anastrozole has been researched along with megestrol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G | 1 |
| Blomqvist, CP; Buzdar, AU; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Lee, D; Steinberg, M; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Rocchi, A; Verma, S | 1 |
| Caruggi, M; Colombo, G; Marchetti, M | 1 |
2 review(s) available for anastrozole and megestrol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
3 trial(s) available for anastrozole and megestrol
| Article | Year |
|---|---|
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 1996 |
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Megestrol; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Quality of Life; Remission Induction; Survival Rate; Triazoles | 1996 |
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Megestrol; Nitriles; Postmenopause; Proportional Hazards Models; Survival Rate; Triazoles | 1998 |
2 other study(ies) available for anastrozole and megestrol
| Article | Year |
|---|---|
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Middle Aged; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2003 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |